Mar 12, 2019 / 07:50PM GMT
Gena Wang - Barclays Bank PLC, Research Division - Research Analyst
Good afternoon, everyone. My name is Gena Wang. I am the SMid-Cap biotech analyst from Barclays.
It's my pleasure to introduce our next speaker Laurie Stelzer, Chief Financial Officer, from Halozyme.
Laurie D. Stelzer - Halozyme Therapeutics, Inc. - Senior VP & CFO
Thank you, Gena, and let me grab the clicker. Okay. Good afternoon, everyone. I am delighted to be here today to talk about Halozyme. Halozyme is a unique biotech company. We have a very unique strategy with a 2 pillar structure for growth. I'm going to talk about both those pillars but both pillars, both ENHANZE and PEGPH20 really will drive a great deal of shareholder value.
Before I get started, the forward-looking statements I'll be making today, I direct you to our SEC filings for a full list of risks and uncertainties.
So as I mentioned, we have 2 pillars for growth, 2 engines for growth in the future. On the left-hand side, you'll see our ENHANZE. This is a drug technology platform. In this
Halozyme Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Mar 13, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers